You are here

Novartis

US benefits manager baulks after Novartis values gene therapy at $4-5 mln

US benefits manager baulks after Novartis values gene therapy at $4-5 mln

Yahoo/Reuters

Express Scripts

spinal muscular atrophy

Flag link:

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries

BioSpace

developing countries

Flag link:

Novartis confident in Gilenya despite FDA call out

Novartis confident in Gilenya despite FDA call out

Biopharma Dive

multiple sclerosis

Flag link:

Novartis CEO Is Going All in With Some Big Bets on R&D

Novartis CEO Is Going All in With Some Big Bets on R&D

BioSpace

Flag link:

Novartis focusing on cutting CAR-T costs ahead of EU launches

Novartis focusing on cutting CAR-T costs ahead of EU launches

Pharmaforum

Flag link:

Novartis' blood disorder drug gets FDA approval for expanded use

Novartis' blood disorder drug gets FDA approval for expanded use

Reuters

severe aplastic anemia

Flag link:

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Flag link:

Novartis’ CAR-T cancer drug available on NHS to young people

Novartis’ CAR-T cancer drug available on NHS to young people

Pharmaforum

refractory B-cell acute lymphoblastic leukemia

Flag link:

It's Lights Out For Novartis And Verily's Glucose Monitoring 'Smart Lens' Project

It's Lights Out For Novartis And Verily's Glucose Monitoring 'Smart Lens' Project

Forbes

blood glucose monitoring

Flag link:

Novartis Calls for FDA Enforcement Against Biosimilar Misinformation

Novartis Calls for FDA Enforcement Against Biosimilar Misinformation

RAPS.org

citizen petitions

Flag link:

Novartis 'completely committed' to Sandoz, has no split-off plan

Novartis 'completely committed' to Sandoz, has no split-off plan

Yahoo/Reuters

Flag link:

Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects

Fierce Pharma

Flag link:

Ionis, Akcea succeed in heart drug trial, setting up Novartis decision

Ionis, Akcea succeed in heart drug trial, setting up Novartis decision

Biopharma Dive

Akcea Therapeutics

Ionis Pharmaceuticals

clinical trials

AKCEA-APO(a)-Lrx

Flag link:

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study

Endpoints

Flag link:

As Novartis' other cancer launches struggle, Lutathera gets off to flying start

As Novartis' other cancer launches struggle, Lutathera gets off to flying start

Fierce Pharma

neuroendocrine tumors

Flag link:

Novartis Plans for 60 Regulatory Filings Over the Next Three Years

Novartis Plans for 60 Regulatory Filings Over the Next Three Years

BioSpace

drug development

Flag link:

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

Endpoints

spinal muscular atrophy

Flag link:

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data

Fierce Pharma

Flag link:

Novartis abandons effort for U.S. approval of biosimilar rituximab

Novartis abandons effort for U.S. approval of biosimilar rituximab

Yahoo/Reuters

Flag link:

NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?

NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?

Xtalks

Flag link:

Pages